| Biotech Trades for the 2010 ASCO Conference Wealth Daily submits:By Ian CooperNothing has the power to send a biotech stock to the moon like the FDA...Complete Story » seekingalpha.com |
Latisse Faces Patent Challenge The FDA said a company is challenging Allergan's patent protection for the eyelash drug Latisse, looking to make a generic version. online.wsj.com |
HealthSouth Swings to Profit HealthSouth swung to a profit following prior-year charges as revenue increased. The company raised its 2010 earnings target. online.wsj.com |
Amgen Recalls Some Procrit, Epogen Amgen is recalling certain lots of anemia drugs Epogen and Procrit because they may contain "extremely thin" glass flakes. online.wsj.com |
Why Pharmathene Could Go From $2 to $20 James Altucher submits:In the biotech sector I try to find stocks that have minimal downside but potential for 10x returns. Back in July, 2007, for instance, I took a lot of heat writing bullishly about DNDN on TheStreet.com. More recently, I wrote this article for the Wall St Journal on June 30 about Pharmathene (PIP) when it was at 1.56. I listed three catalysts then and suggested that the stock should minimally be catapulted in the $7-10 range. I wanted to give an update on what's gone on since then and why I think the stock could eventually be even double what I initially thought. First off, the stock is now at $2 after a competitive company, SIGA, three days ago received a contract from the government that could be worth conceivably up to $2.8bb for its smallpox antiviral product.Complete Story » seekingalpha.com |